Bibliotecas PUC-SP - Busca Integrada

The “rights” of precision drug development for Alzheimer’s disease

Por Jeffrey Cummings, Howard H. Feldman, Philip Scheltens
Publicado no Alzheimer’s Research & Therapy (2019-08-01)

Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease

Por Gary E. Gibson, Howard H. Feldman, Sheng Zhang, Sarah A. Flowers, José A. Luchsinger
Publicado no Frontiers in Medicine (2022-10-01)

Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemp...

Por Elizabeth Finger, Scott Berry, Jeffrey Cummings, Kristy Coleman, Robin Hsiung, Howard H. Feldman, Adam Boxer
Publicado no Alzheimer’s Research & Therapy (2018-09-01)

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease

Por Gabriel L Ketron, Felix Grun, Joshua D Grill, Howard H Feldman, Robert A Rissman, Gregory J Brewer
Publicado no Alzheimer’s Research & Therapy (2025-03-01)

Tailoring implementation strategies for the healthy actions and lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program: Lessons learned from a survey study

Por Sara Moukarzel, Carlos E.E. Araujo-Menendez, Eliza Galang, Zvinka Z. Zlatar, Howard H. Feldman, Sarah J. Banks
Publicado no The Journal of Prevention of Alzheimer's Disease (2025-03-01)

Implications of practice effects for the design of Alzheimer clinical trials

Por Jasmin A. Duehring, Diane M. Jacobs, Michael L. Thomas, Hiroko H. Dodge, Howard H. Feldman, Steven D. Edland
Publicado no Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2025-07-01)

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease

Por Ben Boyarko, Sonia Podvin, Barry Greenberg, Jeremiah D. Momper, Yadong Huang, Yadong Huang, William H. Gerwick, William H. Gerwick, Anne G. Bang, Luisa Quinti, Ana Griciuc, Doo Yeon Kim, Rudolph E. Tanzi, Howard H. Feldman, Howard H. Feldman, Vivian Hook, Vivian Hook
Publicado no Frontiers in Pharmacology (2023-08-01)

Developing the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program

Por Sara Moukarzel, Zvinka Z. Zlatar, Sheri J. Hartman, Derek Lomas, Howard H. Feldman, Sarah J. Banks, HALT‐AD Study Group
Publicado no Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2024-01-01)

Exploring the usability and perceived benefits of Brain Health PRO: An online educational program for healthy brain aging

Por George Philip, Alexandra J Fiocco, Sylvie Belleville, Howard Chertkow, Howard H Feldman, Manuel Montero-Odasso, Haakon B Nygaard, Marie Y Savundranayagam
Publicado no Digital Health (2025-11-01)

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomat...

Por Jeffrey L. Cummings, Alireza Atri, Howard H. Feldman, Oskar Hansson, Mary Sano, Filip K. Knop, Peter Johannsen, Teresa León, Philip Scheltens
Publicado no Alzheimer’s Research & Therapy (2025-01-01)

Multidomain trials to prevent dementia: addressing methodological challenges

Por Manuel Montero-Odasso, G Y Zou, Nellie Kamkar, Howard H. Feldman, Sylvie Belleville, Howard Chertkow, Haakon B Nygaard, Surim Son, Mark Speechley
Publicado no Alzheimer’s Research & Therapy (2022-07-01)

Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures

Por Sarah J. Banks, Yuqi Qiu, Chun Chieh Fan, Anders M. Dale, Jingjing Zou, Brianna Askew, Howard H. Feldman, For the Alzheimer's Disease Neuroimaging Initiative
Publicado no Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2020-01-01)

Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controll...

Por Nicholas C. Cullen, Petr Novak, Duygu Tosun, Branislav Kovacech, Jozef Hanes, Eva Kontsekova, Michal Fresser, Stefan Ropele, Howard H. Feldman, Reinhold Schmidt, Bengt Winblad, Norbert Zilka
Publicado no EBioMedicine (2024-01-01)

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective

Por Khushbu J. Patel, David Yang, Howard H. Feldman, Ging‐Yuek R. Hsiung, Haakon B. Nygaard, John R. Best, Emily Dwosh, Julie M. Robillard, Mari L. DeMarco
Publicado no Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2024-04-01)

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217

Por Branislav Kovacech, Nicholas C. Cullen, Petr Novak, Jozef Hanes, Eva Kontsekova, Stanislav Katina, Vojtech Parrak, Michal Fresser, Jeroen Vanbrabant, Howard H. Feldman, Bengt Winblad, Erik Stoops, Eugeen Vanmechelen, Norbert Zilka
Publicado no Alzheimer’s Research & Therapy (2024-11-01)

Home EEG sleep assessment shows reduced slow‐wave sleep in mild–moderate Alzheimer's disease

Por Brianne A. Kent, Amelia A. Casciola, Sebastiano K. Carlucci, Meghan Chen, Sam Stager, Maryam S. Mirian, Penelope Slack, Jason Valerio, Martin J. McKeown, Howard H. Feldman, Haakon B. Nygaard
Publicado no Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2022-01-01)

Synaptic dysfunction in progranulin-deficient mice

Por Terri L. Petkau, Scott J. Neal, Austen Milnerwood, Ada Mew, Austin M. Hill, Paul Orban, Jenny Gregg, Ge Lu, Howard H. Feldman, Ian R.A. Mackenzie, Lynn A. Raymond, Blair R. Leavitt
Publicado no Neurobiology of Disease (2012-02-01)

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia

Por Dawn C. Matthews, Aaron Ritter, Ronald G. Thomas, Randolph D. Andrews, Ana S. Lukic, Carolyn Revta, Jefferson W. Kinney, Babak Tousi, James B. Leverenz, Howard Fillit, Kate Zhong, Howard H. Feldman, Jeffrey Cummings
Publicado no Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2021-01-01)

Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers

Por Karteek Popuri, Emma Dowds, Mirza Faisal Beg, Rakesh Balachandar, Mahadev Bhalla, Claudia Jacova, Adrienne Buller, Penny Slack, Pheth Sengdy, Rosa Rademakers, Dana Wittenberg, Howard H. Feldman, Ian R. Mackenzie, Ging-Yuek R. Hsiung
Publicado no NeuroImage: Clinical (2018-01-01)

Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

Por Lon S. Schneider, Yuqi Qiu, Ronald G. Thomas, Carol Evans, Diane M. Jacobs, Shelia Jin, Jeffrey A. Kaye, Andrea Z. LaCroix, Karen Messer, David P. Salmon, Mary Sano, Kimberly Schafer, Howard H. Feldman
Publicado no Alzheimer’s Research & Therapy (2021-12-01)